News
Sanofi buys Vigil Neuroscience for $470m
Digest more
Sanofi relocated 2,000 employees to a new $130M Morristown flagship office at M Station West in May, leaving Bridgewater.
Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...
Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its ...
Global healthcare company Sanofi yesterday formally opened its new flagship US offices at M Station West in Morristown.
Houman Ashrafian, Head of R&D at Sanofi. In this episode, Ashrafian joins Bloomberg Intelligence analyst Sam Fazeli to unpack how AI-powered portfolio construction, franchise-based innovation and a ...
The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has granted approval to ...
Explore more
The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...
GSK Plc won US approval for its drug to treat a deadly lung disease, ramping up competition with rival Sanofi.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results